TABLE 1.
Characterization of blaIMP-8-carrying R. planticola clinical isolates
| Drug or resistance profile | MICa (μg/ml) or characteristic of R. planticola clinical isolate |
|
|---|---|---|
| Isolate 139 (case 1) | Isolate 193 (case 2) | |
| Carbapenems | ||
| Imipenem | 4 (R) | 4 (R) |
| Meropenem | 2 (I) | 2 (I) |
| Doripenem | >2 (R) | >2 (R) |
| Ertapenem | 1 (R) | 2 (R) |
| Cephems | ||
| Cefepime | 16 (I) | >16 (R) |
| Cefoxitin | >16 (R) | >16 (R) |
| Ceftazidime | >16 (R) | >16 (R) |
| Cefazolin | >16 (R) | >16 (R) |
| Cefuroxime | >16 (R) | >16 (R) |
| Cefotaxime | >32 (R) | >32 (R) |
| Aztreonam | <1 (S) | <1 (S) |
| Ticarcillin-clavulanic acid | >64 (R) | >64 (R) |
| Piperacillin-tazobactam | 16 (S) | 8 (S) |
| Trimethoprim-sulfamethoxazole | >2 (R) | >2 (R) |
| Tigecycline | 0.5 | 0.5 |
| Amikacin | <4 (S) | <4 (S) |
| Gentamicin | 2 (S) | 2 (S) |
| Colistin | <0.5 (S) | 1 (S) |
| Nalidixic acid | >8 | >8 |
| Ciprofloxacin | 0.5 (S) | 1 (S) |
| Levofloxacin | 1 (S) | 1 (S) |
| Resistance profiles | ||
| Outer membrane porins | OmpK35 (−), OmpK36 (−) | OmpK35 (−), OmpK36 (+) |
| Class I integron | dfrA12-orfF-aadA2 | dfrA12-orfF-aadA2 |
| PMQRb genes | qnrB2 | qnrB2 |
a
MICs were determined by the agar dilution method. R, resistant; S, susceptible; I, intermediate.
b
PMQR, plasmid-mediated quinolone resistance genes, including qnrA, qnrB, qnrS, qepA, aac(6′)-Ib-cr, armA, and rmtB.